2025-03-12 11:30:38
Latest Post
W S Industries India Ltd's subsidiary to acquire 54.89 acres land for Rs. 46.66 crores
IKS Health wins Top Honors in 2025 Black Book Survey in New AI-Driven RCM Category
Mipco Seamless Rings Gujarat Ltd approves shifting of registered office
Crizac Limited gets Sebi Nod for Rs 1,000 cr IPO
REC Limited inaugurates REC Experience Center
Stock Report
Mankind Pharma Ltd consolidated Q2 FY2023-24 PAT climbs to Rs. 501.02 crores
Posted On : 2023-10-31 23:39:32( TIMEZONE : IST )
Mankind Pharma Limited has reported Consolidated financial results for the period ended September 30, 2023.
Financial Results (Q2 FY2024) - QoQ Comparison
The company has reported total income of Rs. 2768.0774 crores during the period ended September 30, 2023 as compared to Rs. 2637.2364 crores during the period ended June 30, 2023.
The company has posted net profit / (loss) of Rs. 501.0260 crores for the period ended September 30, 2023 as against net profit / (loss) of Rs. 486.8722 crores for the period ended June 30, 2023.
The company has reported EPS of Rs. 12.49 for the period ended September 30, 2023 as compared to Rs. 12.14 for the period ended June 30, 2023.
| Financials | Q2 FY2024 | Q1 FY2024 | % Change |
| Total Income | ₹ 2768.0774 crs | ₹2637.2364 crs |  4.96% |
| Net Profit | ₹501.0260 crs | ₹486.8722 crs | 2.91% |
| EPS | ₹12.49 | ₹12.14 | 2.88% |
Financial Results (Q2 FY2024) - YoY Comparison
The company has reported total income of Rs. 2768.0774 crores during the period ended September 30, 2023 as compared to Rs.2453.2123 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs.501.0260 crores for the period ended September 30, 2023 as against net profit / (loss) of Rs.419.7111 crores for the period ended September 30, 2022.
The company has reported EPS of Rs.12.49 for the period ended September 30, 2023 as compared to Rs.10.48 for the period ended September 30, 2022.
| Financials | Q2 FY2024 | Q2 FY2023 | % Change |
| Total Income | ₹ 2768.0774 crs | ₹2453.2123 crs | 12.83% |
| Net Profit | ₹501.0260 crs | ₹419.7111 crs | 19.37% |
| EPS | ₹12.49 | ₹10.48 | 19.18% |
Financial Results (Half Year Ended FY2024) - YoY Comparison
The company has reported total income of Rs.5405.3138 crores during the 6 Months period ended September 30, 2023 as compared to Rs.4649.7479 crores during the 6 Months period ended September 30, 2022.
The company has posted net profit / (loss) of Rs.987.8982 crores for the 6 Months period ended September 30, 2023 as against net profit / (loss) of Rs.712.2681 crores for the 6 Months period ended September 30, 2022.
The company has reported EPS of Rs.24.63 for the 6 Months period ended September 30, 2023 as compared to Rs.17.78 for the 6 Months period ended September 30, 2022.
| Financials | Half Year Ended FY2024 | Half Year Ended FY2023 | % Change |
| Total Income | ₹5405.3138 crs | ₹4649.7479 crs | 16.25% |
| Net Profit | ₹987.8982 crs | ₹712.2681 crs | 38.70% |
| EPS | ₹24.63 | ₹17.78 | 38.53% |
Shares of Mankind Pharma Limited was last trading in BSE at Rs. 1741.10 as compared to the previous close of Rs. 1753.30. The total number of shares traded during the day was 4515 in over 744 trades.
The stock hit an intraday high of Rs. 1782.85 and intraday low of 1736.00. The net turnover during the day was Rs. 7897345.00.
